Your health is
our priority
our priority
Kowa Pharmaceutical Asia Pte.Ltd.
News & Events
-
Initiation of a new Phase 3 global clinical study for the Indication of Fuchs endothelial corneal dystrophy [Development code: K-321]April 6, 2023
-
Initiation of a Phase 3 global clinical study for the Indication of Fuchs endothelial corneal dystrophy [Development code: K-321]March 22, 2023
-
Kowa Pharmaceutical Asia Pte. Ltd,. has launched a new website.September 1, 2022
-
Sales ¥573,930m
Fiscal year ended
March 31, 2024,
Kowa Group consolidated -
Employees 7,974
As of March 2024,
Kowa Group consolidated -
Major subsidiaries 69
Major Subsidiaries & Affiliates in Japan,
Asia, North America, Latin America, and Europe
Rich in knowledge and experience with a vision of a better world
Our Products
The Pharmaceutical Business Unit conducts research, development, and manufacturing of OTC drugs, healthcare products, supplements, Prescription drugs, and medical devices (ophthalmic medical devices, intraocular lenses, etc.) based on flexible ideas and advanced technology.
Our Treatment areas
Kowa’s wide variety of prescription medicines include oral agents for the treatment of cardiovascular diseases as our specialty segments, topical agents for eye.